These product press releases are intended for use in the United States only. Countries outside of the U.S. may have different regulatory requirements and review practices that may require referencing different information.

Aug. 3, 2011

Merck and Serum Institute Announce Collaboration to Develop and Expand Global Access to Pneumococcal Conjugate Vaccine (PCV)

GARDASIL^® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant]

Full Prescribing Information

Patient Product Information

Oct. 26, 2011		New England Journal of Medicine Publishes Additional Efficacy and Safety Data for GARDASIL® in Males
Oct. 25, 2011		CDC Advisory Committee on Immunization Practices Votes for Expanded Use of GARDASIL® in Boys and Young Men
Sept. 13, 2011		Merck Partners with Susan G. Komen for the Cure® on Historic Initiative to Help Address Cervical and Breast Cancer in Developing Nations
July 1, 2011		Merck Receives Approval to Market GARDASIL®, ZOLINZA® and CUBICIN® in Japan
Apr. 25, 2011		Rwanda, Merck and QIAGEN Launch Africa's First Comprehensive Cervical Cancer Prevention Program Incorporating Both HPV Vaccination and HPV Testing
Apr. 06, 2011		U.S. Prescribing Information for GARDASIL® Updated; Indication Not Granted for Use in Adult Women
Feb. 02, 2011		New England Journal of Medicine Publishes Efficacy and Safety Data for GARDASIL® in Males

ROTATEQ^® [rotavirus vaccine, live, oral, pentavalent] Oral Solution

Full Prescribing Information

Patient Product Information

Apr. 21, 2011		Merck and Sanofi Pasteur Initiate Phase III Study in the United States of Pediatric Combination Vaccine to Help Prevent Six Infectious Diseases

ZOSTAVAX^® [zoster vaccine live]

Full Prescribing Information

Patient Product Information

Mar. 25, 2011		FDA Expands Indication for ZOSTAVAX®, Merck's Shingles Vaccine,to Include Adults Ages 50 to 59